Fixed dose rivaroxaban can be used in extremes of bodyweight: A population pharmacokinetic analysis
- 31 August 2020
- journal article
- research article
- Published by Elsevier BV in Journal of Thrombosis and Haemostasis
- Vol. 18 (9), 2296-2307
- https://doi.org/10.1111/jth.14948
Abstract
No abstract availableThis publication has 33 references indexed in Scilit:
- Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation: a cross-sectional studyBMJ Open, 2013
- Population Pharmacokinetics of Enoxaparin During the Antenatal PeriodCirculation, 2013
- Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studiesThrombosis Journal, 2013
- Anticoagulating obese patients in the modern eraBritish Journal of Haematology, 2011
- A dose-ranging study evaluating once-daily oral administration of the factor Xa inhibitor rivaroxaban in the treatment of patients with acute symptomatic deep vein thrombosis: the Einstein–DVT Dose-Ranging StudyBlood, 2008
- Lean body mass normalizes the effect of obesity on renal functionBritish Journal of Clinical Pharmacology, 2008
- Body Weight Has Limited Influence on the Safety, Tolerability, Pharmacokinetics, or Pharmacodynamics of Rivaroxaban (BAY 59‐7939) in Healthy SubjectsThe Journal of Clinical Pharmacology, 2007
- Perl-speaks-NONMEM (PsN)—a Perl module for NONMEM related programmingComputer Methods and Programs in Biomedicine, 2004
- Factors affecting warfarin requirementsEuropean Journal of Clinical Pharmacology, 1979
- Prediction of Creatinine Clearance from Serum CreatinineNephron, 1976